Accessibility Menu
Arrow-Thin-Down
S&P 500
6,716.09
+0.2%
+16.71
Arrow-Thin-Down
DJI
46,993.26
+0.1%
+46.85
Arrow-Thin-Down
NASDAQ
22,479.53
+0.5%
+105.35
Arrow-Thin-Down
Bitcoin
$74,089.00
+0.0%
+$9.00
Arrow-Thin-Down
AMZN
$215.20
+1.6%
+$3.46
Arrow-Thin-Down
GOOG
$309.33
+1.6%
+$4.91
Arrow-Thin-Down
META
$622.43
-0.8%
-$5.02
Arrow-Thin-Down
MSFT
$399.44
-0.1%
-$0.51
Arrow-Thin-Down
NVDA
$181.86
-0.7%
-$1.36
Arrow-Thin-Down
TSLA
$398.63
+0.8%
+$3.07
Most Active StocksDaily Stock GainersDaily Stock Losers

Gilead Earnings: Can Sovaldi Reach $3 Billion?

Sovaldi beat analyst expectations last quarter -- could it again?

By Michael Douglass and Dave Williamson – Jul 21, 2014 at 5:00PM EST

Gilead Sciences (GILD 0.56%) reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi sales crushing their expectations. Could Gilead surprise to the upside again? Watch the video below for our take.

Read Next

About the Author

Michael Douglass
Former Deputy Managing Editor, Fool.com. I started in Healthcare, but you'll find me writing regularly about biotech, dividend stocks, and personal finance.
TMFEnterprise

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
NASDAQ: GILD
$144.40
(-0.56%)-$0.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services